Supported by a new Strategic Partnership Grant from the Michigan State University Research Foundation, an interdisciplinary team will establish a framework on MSU’s campus that streamlines the development of a promethium-149-based radiopharmaceutical as an effective prostate cancer therapeutic. This integrated system will use cutting-edge facilities including the Facility for Rare Isotope Beams, or FRIB; the Institute for Quantitative Health Science and Engineering, better known as IQ; as well as newly expanded radiochemistry laboratories in MSU’s Department of Chemistry.
Calculating the energy levels and their properties in a nucleus is a formidable task. The nuclear shell model has been very successful in describing many properties of atomic nuclei, such as their excitation energy spectrum. The shortcomings of this model became apparent when facilities dedicated to the production and study of radioactive isotopes, such as FRIB, began operations. Now, writing in Nature Physics, Alexandra Gade, professor of physics at FRIB and in MSU's Department of Physics and Astronomy and FRIB scientific director, and collaborators have measured the features of the neutron-rich nucleus chromium-62, which belongs to one of those islands of inversion, as predicted by shell model calculations.
Supported by a new Strategic Partnership Grant from the Michigan State University Research Foundation, an interdisciplinary team will establish a framework on MSU’s campus that streamlines the development of a promethium-149-based radiopharmaceutical as an effective prostate cancer therapeutic. This integrated system will use cutting-edge facilities including the Facility for Rare Isotope Beams, or FRIB; the Institute for Quantitative Health Science and Engineering, better known as IQ; as well as newly expanded radiochemistry laboratories in MSU’s Department of Chemistry.
Supported by a new Strategic Partnership Grant from the Michigan State University Research Foundation, an interdisciplinary team will establish a framework on MSU’s campus that streamlines the development of a promethium-149-based radiopharmaceutical as an effective prostate cancer therapeutic. This integrated system will use cutting-edge facilities including the Facility for Rare Isotope Beams, or FRIB; the Institute for Quantitative Health Science and Engineering, better known as IQ; as well as newly expanded radiochemistry laboratories in MSU’s Department of Chemistry.
A recent paper in Nature Physics – written by Alexandra Gade, professor of physics at FRIB and in MSU's Department of Physics and Astronomy and FRIB scientific director, and Michael Thoenneson, University Distinguished Professor of physics at MSU – highlights isotope discovery, including a feature on FRIB.